Danaher forecasts 3%-4% 2026 core revenue growth and raises adjusted EPS to $8.45-$8.60 following Masimo close (NYSE:DHR)

Danaher (DHR) has raised its full-year adjusted EPS guidance to $8.45–$8.60, reflecting an upward revision following the successful close of the Masimo acquisition. The guidance raise coupled with Q2 earnings beats signals management confidence in both organic momentum and near-term synergy realization. This represents a material earnings revision catalyst, particularly relevant given the acquisition integration timeline and the company's prior strategic commentary.

The 3%–4% core revenue growth forecast for 2026 reflects a moderating but stable outlook amid macro uncertainty. However, the EPS guidance expansion outpaces revenue growth expectations, indicating meaningful operational leverage and/or margin accretion from the Masimo deal. This operating margin expansion is material for investor positioning in diversified conglomerates trading on earnings power rather than pure top-line momentum.

Life Sciences segment strength is providing fundamental support for the revised outlook, though bioprocess timing risks remain a disclosed headwind. The timing uncertainty around bioprocess recovery is a key monitoring point; if this segment accelerates ahead of guidance, upside surprise potential exists. Conversely, delays could pressure 2026 execution. The balance between organic strength and M&A-driven accretion will define investor confidence in execution.

Sector implication: The earnings guide raise and Masimo integration success reinforce DHR's positioning as a resilient healthcare-industrials hybrid. This supports a tactical bullish signal for diversified industrials and health care equipment exposure, particularly for investors positioned on quality and earnings resilience themes.